92 related articles for article (PubMed ID: 20629525)
21. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
22. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
23. Serum Ca 125 levels in children with acute leukemia and lymphoma.
Birgen D; Ertem U; Duru F; Sahin G; Yüksek N; Bozkurt C; Karacan CD; Aksoy C
Leuk Lymphoma; 2005 Aug; 46(8):1177-81. PubMed ID: 16085559
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors in non-Hodgkin's lymphomas].
Mayáns J; Sanz G; Monzó E; Sancho-Tello R; Carrera MD; Figueres J; Sanz MA
Rev Clin Esp; 1987 May; 180(8):420-5. PubMed ID: 3616025
[No Abstract] [Full Text] [Related]
26. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
27. [Clinically relevant prognostic factors in malignant lymphoma].
Engelhard M; Löffler M
Internist (Berl); 1993 Feb; 34(2):127-31. PubMed ID: 8454425
[No Abstract] [Full Text] [Related]
28. Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.
Chachaj A; Wiśniewski J; Rybka J; Butrym A; Biedroń M; Krzystek-Korpacka M; Fleszar MG; Karczewski M; Wróbel T; Mazur G; Gamian A; Szuba A
PLoS One; 2018; 13(5):e0197148. PubMed ID: 29787597
[TBL] [Abstract][Full Text] [Related]
29. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
Melani C; Roschewski M
Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
[TBL] [Abstract][Full Text] [Related]
30. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
31. [Non-Hodgkin's lymphomas. II. Prognostic factors].
San Miguel JF; Tomás JF; Martín MJ; Ríos A; Moraleda JM; Cañizo MC; González M; Nieto MJ; Sánchez J; López Borrasca A
Sangre (Barc); 1988 Oct; 33(5):367-71. PubMed ID: 3247618
[No Abstract] [Full Text] [Related]
32. Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET.
Toth DF; Raderer M; Wadsak W; Karanikas G
Anticancer Res; 2013 Aug; 33(8):3341-5. PubMed ID: 23898101
[TBL] [Abstract][Full Text] [Related]
33. The clinical value of tumour markers in the management of ovarian cancer.
Rustin GJ
Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
[No Abstract] [Full Text] [Related]
34. [Level of CA125 and hemoglobin as prognostic factors ovarian cancer].
Chovanec J; Bienertová-Vasků J; Dostálová Z; Minár L
Ceska Gynekol; 2009 Aug; 74(4):269-73. PubMed ID: 20564980
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in malignant lymphomas (Hodgkin and non-Hodgkin).
Ascari E; Gobbi PG
Acta Haematol; 1987; 78 Suppl 1():146-50. PubMed ID: 3124438
[TBL] [Abstract][Full Text] [Related]
36. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
37. Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.
Allen GW; Forouzannia A; Bailey HH; Howard SP
Gynecol Oncol; 2004 Sep; 94(3):811-3. PubMed ID: 15350377
[TBL] [Abstract][Full Text] [Related]
38. [Serum levels of mm23-H1 protein and their clinical implications in malignant lymphoma].
Niitsu N
Rinsho Ketsueki; 2001 Dec; 42(12):1155-61. PubMed ID: 11828717
[No Abstract] [Full Text] [Related]
39. HE4 and its evolving role in assessing tumor prognosis in gynecological and systemic malignancies.
Kapoor S
Arch Gynecol Obstet; 2013 Sep; 288(3):713. PubMed ID: 23494198
[No Abstract] [Full Text] [Related]
40. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
